Olav Engebraaten
Overview
Explore the profile of Olav Engebraaten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1001
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Egeland E, Seip K, Skourti E, Oy G, Pettersen S, Pandya A, et al.
Br J Cancer
. 2024 Oct;
131(10):1656-1667.
PMID: 39390250
Background: Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with...
2.
Fleischer T, Haugen M, Ankill J, Silwal-Pandit L, Borresen-Dale A, Hedenfalk I, et al.
Mol Oncol
. 2024 Apr;
18(8):2042-2059.
PMID: 38671580
Treatment with the anti-angiogenic drug bevacizumab in addition to chemotherapy has shown efficacy for breast cancer in some clinical trials, but better biomarkers are needed to optimally select patients for...
3.
Haugen M, von der Lippe Gythfeldt H, Egeland E, Svartdal Normann L, Pandya A, Vedin L, et al.
Mol Oncol
. 2023 Jun;
17(10):2041-2055.
PMID: 37341140
Liver X receptors (LXRs) are nuclear transcription factors important in the regulation of cholesterol transport, and glucose and fatty acid metabolism. The antiproliferative role of LXRs has been studied in...
4.
Svartdal Normann L, Haugen M, Hongisto V, Aure M, Leivonen S, Kristensen V, et al.
PLoS One
. 2023 Jan;
18(1):e0280507.
PMID: 36706086
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of this disease. Targeted treatment has improved outcome, but there is still a need for new therapeutic...
5.
Fusser M, Overbye A, Pandya A, Morch Y, Borgos S, Kildal W, et al.
J Control Release
. 2022 Jul;
349:1.
PMID: 35792388
No abstract available.
6.
Mo T, Brandal S, Kohn-Luque A, Engebraaten O, Kristensen V, Fleischer T, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267636
The purpose of the present study is to investigate if consumption and supply hypoxia (CSH) MR-imaging can depict breast cancer hypoxia, using the CSH-method initially developed for prostate cancer. Furthermore,...
7.
Engebraaten O, Yau C, Berg K, Borgen E, Garred O, Berstad M, et al.
Nat Commun
. 2021 Nov;
12(1):6427.
PMID: 34741021
HER2 is a predictive biomarker for HER2-targeted therapeutics. For antibody-drug conjugates (ADCs; e.g., trastuzumab emtansine (T-DM1)), HER2 is utilized as a transport gate for cytotoxic agents into the cell. ADC...
8.
Haugen M, Lingjaerde O, Hedenfalk I, Garred O, Borgen E, Loman N, et al.
JCO Precis Oncol
. 2021 May;
5.
PMID: 34036235
Purpose: Antiangiogenic therapy using bevacizumab has proven effective for a number of cancers; however, in breast cancer (BC), there is an unmet need to identify patients who benefit from such...
9.
Barkovskaya A, Goodwin C, Seip K, Hilmarsdottir B, Pettersen S, Stalnecker C, et al.
Mol Oncol
. 2021 Mar;
15(8):2026-2045.
PMID: 33759347
Cellular phenotype plasticity between the epithelial and mesenchymal states has been linked to metastasis and heterogeneous responses to cancer therapy, and remains a challenge for the treatment of triple-negative breast...
10.
Kruger K, Silwal-Pandit L, Wik E, Straume O, Stefansson I, Borgen E, et al.
Sci Rep
. 2021 Feb;
11(1):3388.
PMID: 33564016
A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential predictive value...